Endocrinol Metab.  2024 Oct;39(5):758-766. 10.3803/EnM.2024.1950.

Comparison of Thyroid Size-Specific Radioiodine Dose and New Modified Dose Calculation in the Treatment of Graves’ Disease

• Wongsuttilert A
• Thamcharoen R
• Maiprasert Y
• Siriwong S

• KMID: 2560284
• DOI: http://doi.org/10.3803/EnM.2024.1950

Abstract

Background
Previous studies of fixed-dose radioiodine therapy (RIT) for Graves’ disease (GD) have utilized a variety of techniques and reported differing success rates. This study sought to compare the efficacy of RIT using two fixed-dose protocols and to estimate the optimal radioiodine (RAI) activity for the treatment of GD.
Methods
This retrospective trial enrolled 658 patients with GD who received RIT between January 2014 and December 2021. Participants were divided into two groups: protocol 1, which utilized a thyroid size-specific RAI dose, and protocol 2, which employed a modified dose calculation approach. The primary outcome assessed was the presence of euthyroidism or hypothyroidism at the 6-month follow-up. The success rates of RIT were compared between the two protocols.
Results
The RIT success rate was marginally lower for protocol 2 than for protocol 1 (63.6% vs. 67.2%); however, the risk of treatment failure did not differ considerably between the groups (relative risk, 1.1089; 95% confidence interval, 0.8937 to 1.3758; P=0.3477). The median RAI activity associated with protocol 2 was lower than that for protocol 1 (10.7 mCi vs. 15.0 mCi, P=0.0079), and the frequency of hypothyroidism was significantly lower in the protocol 2 group (39.0% vs. 48.9%, P=0.0117).
Conclusion
The success rate of the modified dose calculation protocol was comparable to that of the thyroid size-specific RAI dose protocol. The former approach reduced RAI activity and the incidence of hypothyroidism following RIT without compromising the success rate.

Keyword

Fixed dose; Graves disease; Radioactive iodine treatment; Success rate

Figure

• 

Reference

1. Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association guideline for the management of Graves’ hyperthyroidism. Eur Thyroid J. 2018; 7:167–86.

2. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016; 26:1343–421.

3. Christou N, Mathonnet M. Complications after total thyroidectomy. J Visc Surg. 2013; 150:249–56.

4. Sundaresh V, Brito JP, Thapa P, Bahn RS, Stan MN. Comparative effectiveness of treatment choices for Graves’ hyperthyroidism: a historical cohort study. Thyroid. 2017; 27:497–505.

5. Donovan PJ, McLeod DS, Little R, Gordon L. Cost-utility analysis comparing radioactive iodine, anti-thyroid drugs and total thyroidectomy for primary treatment of Graves’ disease. Eur J Endocrinol. 2016; 175:595–603.

6. Parameswaran R, de Jong MC, Kit JL, Sek K, Nam TQ, Thang TV, et al. 2021 Asia-Pacific Graves’ disease consortium survey of clinical practice patterns in the management of Graves’ disease. Endocrine. 2023; 79:135–42.

7. Santos RB, Romaldini JH, Ward LS. A randomized controlled trial to evaluate the effectiveness of 2 regimens of fixed iodine (¹³¹I) doses for Graves disease treatment. Clin Nucl Med. 2012; 37:241–4.

8. El-Kareem MA, Derwish WA, Moustafa HM. Response rate and factors affecting the outcome of a fixed dose of RAI131 therapy in Graves’ disease: a 10-year Egyptian experience. Nucl Med Commun. 2014; 35:900–7.

9. Sfiligoj D, Gaberscek S, Mekjavic PJ, Pirnat E, Zaletel K. Factors influencing the success of radioiodine therapy in patients with Graves’ disease. Nucl Med Commun. 2015; 36:560–5.

10. Sapienza MT, Coura-Filho GB, Willegaignon J, Watanabe T, Duarte PS, Buchpiguel CA. Clinical and dosimetric variables related to outcome after treatment of Graves’ disease with 550 and 1110 MBq of 131I: results of a prospective randomized trial. Clin Nucl Med. 2015; 40:715–9.

11. Zaman MU, Fatima N, Zaman U, Sajjad Z, Zaman A, Tahseen R. Predictive value of pyramidal lobe, percentage thyroid uptake and age for ablation outcome after 15 mCi fixed dose of radioiodine-131 in Graves’ disease. Indian J Nucl Med. 2015; 30:309–13.

12. Fanning E, Inder WJ, Mackenzie E. Radioiodine treatment for graves’ disease: a 10-year Australian cohort study. BMC Endocr Disord. 2018; 18:94.

13. Kiatkittikul P, Raruenrom Y, Theerakulpisut D, Somboonporn C. Success rate of radioactive iodine therapy in Graves’ disease using dose corrected for thyroid gland size. Siriraj Med J. 2021; 73:108–13.

14. Mariani G, Tonacchera M, Grosso M, Orsolini F, Vitti P, Strauss HW. The role of nuclear medicine in the clinical management of benign thyroid disorders, part 1: hyperthyroidism. J Nucl Med. 2021; 62:304–12.

15. Dighe M, Barr R, Bojunga J, Cantisani V, Chammas MC, Cosgrove D, et al. Thyroid ultrasound: state of the art. Part 1: thyroid ultrasound reporting and diffuse thyroid diseases. Med Ultrason. 2017; 19:79–93.

16. Wiersinga WM. Smoking and thyroid. Clin Endocrinol (Oxf). 2013; 79:145–51.

17. Wiersinga WM. Clinical relevance of environmental factors in the pathogenesis of autoimmune thyroid disease. Endocrinol Metab (Seoul). 2016; 31:213–22.

18. Campenni A, Avram AM, Verburg FA, Iakovou I, Hanscheid H, de Keizer B, et al. The EANM guideline on radioiodine therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2023; 50:3324–48.

19. Mitchell AL, Hegedus L, Zarkovic M, Hickey JL, Perros P. Patient satisfaction and quality of life in hypothyroidism: an online survey by the British Thyroid Foundation. Clin Endocrinol (Oxf). 2021; 94:513–20.

20. Tran A, Hyer S. The challenge of thyroid hormone replacement in primary care. J Pharm Clin Res. 2018; 5:555669.

21. Vija Racaru L, Fontan C, Bauriaud-Mallet M, Brillouet S, Caselles O, Zerdoud S, et al. Clinical outcomes 1 year after empiric 131I therapy for hyperthyroid disorders: real life experience and predictive factors of functional response. Nucl Med Commun. 2017; 38:756–63.

22. Aktay R, Rezai K, Seabold JE, Bar RS, Kirchner PT. Four- to twenty-four-hour uptake ratio: an index of rapid iodine-131 turnover in hyperthyroidism. J Nucl Med. 1996; 37:1815–9.

23. Zhang R, Tan J, Wang R, Zhang G, Jia Q, Meng Z, et al. Analysis of risk factors of rapid thyroidal radioiodine-131 turnover in Graves’ disease patients. Sci Rep. 2017; 7:8301.

24. Arora S, Bal C. Is there any need for adjusting 131I activity for the treatment of high turnover Graves’ disease compared to normal turnover patients?: results from a retrospective cohort study validated by propensity score analysis. Nucl Med Mol Imaging. 2021; 55:15–26.

25. Plazinska MT, Sawicka-Gutaj N, Czarnywojtek A, Wolinski K, Kobylecka M, Karlinska M, et al. Radioiodine therapy and Graves’ disease: myths and reality. PLoS One. 2020; 15:e0226495.

26. Kim HJ, Hong G, Hwang J, Kazmi SZ, Kim KH, Kang T, et al. Familial risk of Graves disease among first-degree relatives and interaction with smoking: a population-based study. J Clin Endocrinol Metab. 2023; 108:e502–11.